Compare Medtronic PLC (MDT) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Quantumscape Corp — how do they compare? Medtronic PLC trades at $83.21 (market cap $106.61B), while Quantumscape Corp trades at $6.01 (market cap $3.62B). The key difference: Medtronic PLC is far larger — about 29.5× Quantumscape Corp's market cap, and Medtronic PLC pays a 3.46% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| MDT | QS | |
|---|---|---|
Market Cap | $106.61B | $3.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $18.44 |
52-Week Low | $73.75 | $5.86 |
Enterprise Value | $125.36B | $2.79B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
QuantumScape (QS) trades at $5.91, up 0.85% today, amid a bearish technical trend and negative profitability. The company reported a net loss of $435.05 million in 2025, with cash flow sustained by financing activities. Recent news highlights a joint research agreement with Honda, sparking investor interest in its solid-state battery technology.
The outlook remains speculative, hinging on successful commercialization of its battery technology. Key risks include persistent losses, high cash burn, and competitive pressures. Analyst sentiment is cautious, with no buy ratings and 72.7% hold recommendations, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
